CGTLive’s Weekly Rewind – August 5, 2022

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Allogeneic Cell Therapy Trial to Initiate in Ovarian Cancer

Avenge Bio previously presented positive preclinical data at the ASGCT 2022 meeting.

2. Craig M. McDonald, MD, on Safety and Efficacy of DMD Cell Therapy

The principal investigator of the HOPE-2 trial discussed safety and efficacy of Capricor’s CAP-1002.

3. REGENXBIO's MPSII Gene Therapy Charts Course to Approval

The FDA will consider RGX-121's BLA in an accelerated approval pathway.

4. IND Cleared for Dual-Targeted CAR T Therapy for B-Cell Malignancies

UCART2022 is an allogeneic therapy that targets both CD20 and CD22.

5. IND Halted for T-Cell Malignancy Multiplex-Edited Cell Therapy

Beam Therapeutics submitted an IND for BEAM-201 in June 2022.